PharmAust ready to trial monepantel on humans to fight motor neurone disease

PharmAust progresses flagship Monepantel drug in treating canine lymphoma and COVID-19

Monsoon Communications Twilight Webinar – November 2021

PharmAust AGM 2021

Virtual Investor Briefing – August 2021

Q-Wrapz: Oriel Morrison interviews Roger Aston, executive chairman of PharmAust Ltd (ASX:PAA)

PharmAust progresses flagship Monepantel drug in treating canine lymphoma and COVID-19

Epichem OHD Presentation – Waste To Fuels Technology

PharmAust Webinar – Feb 11th

PharmAust Limited AGM 2020

Auzbiz Interview with Dr Richard Mollard – September 2020

PAA awarded a grant for Phase I trial in Motor Neurone Disease

PharmAust confirms Monepantel’s anti-viral potential in the fight against COVID-19

Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020

PharmAust Virtual Investor Briefing – June 2020

PAA Speech at Med-Tech & Healthcare Investors Night – July 2019

90 Seconds With Spark – PharmAust (ASX:PAA)

Dr Martine Keenan – CEO and Head of Drug Discovery Interview

Proactive Investors Interview with Dr Roger Aston, Executive Chairman of PharmAust (PAA)

PharmAust: New Drug Entering Phase 2 Trials Targeting Multiple Cancers

Interview on RedChip Money Report television program aired on Bloomberg the 2nd and 3rd of January 2016

PharmAust: Developing Targeted Cancer Therapy

Dave Gentry, host of “The RedChip Money Report”, interviews Dr. Roger Aston, Executive Chairman of PharmAust Ltd (ASX: PAA) as aired on Bloomberg​​ TV.

PharmAust Presentation at RedChip’s February 2016 Conference

PharmAust presentation at the RedChip Global Online Microcap Conference on Thursday, February 11, 2016.